Curis Q1 net loss $24.2M, no revenue; cash $15M; clinical milestones ahead

CURIS INC

Net loss of $24.2M ($1.25 per share) vs $10.6M loss in Q1 2025; EPS unchanged due to higher share count.
No revenue in Q1 2026 after sale of Erivedge royalties in Q4 2025; Q1 2025 had $2.4M royalty revenue.
Cash and equivalents $15.0M as of Mar 31; expects runway into H2 2027 contingent on $20.2M Series B warrant exercise.
Closed $80.8M private placement in Jan 2026; initial $20.2M received; warrants exercisable at $0.75 per share.
TakeAim CLL combination trial with zanubrutinib expects dosing of 5th patient mid-2026; PCNSL data in 1H 2027.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

CURIS INC reported for the quarter ended March 31, 2026 results: net income net loss of $24.2 million, or $1.25 per share on both a basic and diluted basis, EPS $1.25 per share on both a basic and diluted basis.

Period: for the quarter ended March 31, 2026
Net income: net loss of $24.2 million, or $1.25 per share on both a basic and diluted basis
EPS: $1.25 per share on both a basic and diluted basis
Result: reported results

Exact text from the filing

On May 12, 2026, Curis, Inc. announced its financial results for the three-month periods ended March 31, 2026.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

CURIS INC filing history →

Source: SEC EDGAR

accession 0001108205-26-000059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.